title: Dementia with Lewy bodies.
abstract: The objective was to summarize recent findings about the clinical features, diagnosis and investigation of dementia with Lewy (DLB) bodies, together with its neuropathology, neurochemistry and genetics. Dementia with Lewy bodies (DLB) is a primary, neurodegenerative dementia sharing clinical and pathological characteristics with both Parkinson's disease (PD) and Alzheimer's disease (AD). Antiubiquitin immunocytochemical staining, developed in the early 1990s, allowed the frequency and distribution of cortical LBs to be defined. More recently, alpha-synuclein antibodies have revealed extensive neuritic pathology in DLB demonstrating a neurobiological link with other "synucleinopathies" including PD and multiple system atrophy (MSA). The most significant correlates of cognitive failure in DLB appear to be with cortical LB and Lewy neurites (LNs) rather than Alzheimer type pathology. Clinical diagnostic criteria for DLB, published in 1996, have been subjected to several validation studies against autopsy findings. These conclude that although diagnostic specificity is high (range 79- 100%, mean 92%), sensitivity is lower (range 0- 83 %, mean, 49%). Improved methods of case detection are therefore required. Fluctuating impairments in attention, visual recognition and construction are more indicative of DLB than AD. Relative preservation of medial temporal lobe volume on structural MRI and the use of SPECT tracers for regional blood flow and the dopamine transporter are the most reliable current biomarkers for DLB. There are no genetic or CSF tests recommended for the diagnosis of DLB at present. Between 15 and 20% of all elderly demented cases reaching autopsy have DLB, making it the most common cause of degenerative dementia after AD. Exquisite, not infrequently fatal, sensitivity to neuroleptic drugs and encouraging reports of the effects of cholinesterase inhibitors on cognitive, psychiatric and neurological features, mean that an accurate diagnosis of DLB is more than merely of academic interest. Dementia developing late in the course of PD shares many of the same clinical and pathological characteristics.
authors.affiliation: Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle, UK.
authors.forename: Ian G
authors.initials: IG
authors.lastname: McKeith
authors.forename: David J
authors.initials: DJ
authors.lastname: Burn
authors.forename: Clive G
authors.initials: CG
authors.lastname: Ballard
authors.forename: Daniel
authors.initials: D
authors.lastname: Collerton
authors.forename: Evelyn
authors.initials: E
authors.lastname: Jaros
authors.forename: Chris M
authors.initials: CM
authors.lastname: Morris
authors.forename: Andrew
authors.initials: A
authors.lastname: McLaren
authors.forename: Elaine K
authors.initials: EK
authors.lastname: Perry
authors.forename: Robert
authors.initials: R
authors.lastname: Perry
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Piggott
authors.forename: John T
authors.initials: JT
authors.lastname: O'Brien
mesh_terms: D000368:Aged; D000483:Alleles; D000544:Alzheimer Disease / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics; D002540:Cerebral Cortex / Q000473:pathology; D003952:Diagnostic Imaging; D005787:Gene Frequency / Q000235:genetics; D005799:Genes, Dominant / Q000235:genetics; D006801:Humans; D016631:Lewy Bodies / Q000473:pathology; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D010300:Parkinson Disease / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D012307:Risk Factors
chemical_list: D053327:Apolipoprotein E4; D001057:Apolipoproteins E